Cargando…

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is primarily metabolized via glucuronidation by the uridine 5′‐diphospho‐glucuronosyltransferase (UGT) isoform UGT1A9. This noncompartmental meta‐analysis of ertugliflozin pharmacokinetics evaluated the relationship between ertugliflozin exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marshall, Jean‐Claude, Liang, Yali, Sahasrabudhe, Vaishali, Tensfeldt, Thomas, Fediuk, Daryl J., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas Kumar, Wood, Linda S., Sweeney, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Pharmacogenomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453771/ https://www.ncbi.nlm.nih.gov/pubmed/33813736 http://dx.doi.org/10.1002/jcph.1866

Ejemplares similares

Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2021)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States
por: Dawra, Vikas Kumar, et al.
Publicado: (2020)

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
por: Imamura, Chiyo K., et al.
Publicado: (2015)

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
por: Callegari, Ernesto, et al.
Publicado: (2020)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Fediuk, Daryl J., et al.
Publicado: (2019)

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers
por: Abdullahi, Sa'ad T., et al.
Publicado: (2019)

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
por: Li, Yinhua, et al.
Publicado: (2019)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p
por: Sutliff, Aimee K., et al.
Publicado: (2019)

Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Development of R packages: ‘NonCompart’ and ‘ncar’ for noncompartmental analysis (NCA)
por: Kim, Hyungsub, et al.
Publicado: (2018)

Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022)

Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System
por: Tsamandouras, N., et al.
Publicado: (2017)

Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice
por: McMillan, JoEllyn M., et al.
Publicado: (2018)

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
por: Scotcher, Daniel, et al.
Publicado: (2017)

Erratum: Development of R packages: ‘NonCompart’ and ‘ncar’ for noncompartmental analysis (NCA)
por: Kim, Hyungsub, et al.
Publicado: (2018)

Overview of Ertugliflozin
por: Nguyen, Vivianne K., et al.
Publicado: (2019)

Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview
por: Perry, Courtney, et al.
Publicado: (2020)

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
por: Raje, Sangeeta, et al.
Publicado: (2018)

In Vitro Generation of Red Blood Cells from Stem Cell and Targeted Therapy
por: Zhou, Ping, et al.
Publicado: (2020)

Claudin-7 Inhibits Proliferation and Metastasis in Salivary Adenoid Cystic Carcinoma Through Wnt/β-Catenin Signaling
por: Ji, Huan, et al.
Publicado: (2020)

Effects of Rapamycin Combined with Cisplatin on Tumor Necrosis Factor TNF-α in MG-63 Cells
por: Han, Tian-Yu, et al.
Publicado: (2020)

The Role of LncRNA H19 in MAPK Signaling Pathway Implicated in the Progression of Bronchopulmonary Dysplasia
por: Mo, Wenhui, et al.
Publicado: (2020)

The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH
por: Xu, Jianfeng, et al.
Publicado: (2020)

Infection of Placental Extravillous Cytotrophoblasts with Human Cytomegalovirus Causes a Treg/Th17 Imbalance at the Maternal–Fetal Interface
por: Qiao, Yuan, et al.
Publicado: (2020)

Long Noncoding RNA ZFAS1 Promotes Progression of NSCLC via Regulating of miR-590-3p
por: Zhou, Yumei, et al.
Publicado: (2020)

A Likely Role for a Novel Cell Therapeutic Target of Transforming Growth Factor-β1 on Radiation Pneumonitis in Lung and Nasopharyngeal Cancer Patients
por: Yin, Qin, et al.
Publicado: (2020)

Enhanced UV Resistance Role of Death Domain–Associated Protein in Human MDA-MB-231 Breast Cancer Cells by Regulation of G2 DNA Damage Checkpoint
por: Shan, Zhiyan, et al.
Publicado: (2020)

MicroRNA-497-5p Functions as a Modulator of Apoptosis by Regulating Metadherin in Ovarian Cancer
por: Liu, Chunyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qb0nd3tr2niidf3p4pc7c1kibu